Search tips
Search criteria 


Logo of jrsocmedLink to Publisher's site
J R Soc Med. 1993 June; 86(6): 355–356.
PMCID: PMC1294488

Xeroderma pigmentosum variant: 5 years of tumour suppression by etretinate.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (661K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Arlett CF, Harcourt SA, Cole J, Green MH, Anstey AV. A comparison of the response of unstimulated and stimulated T-lymphocytes and fibroblasts from normal, xeroderma pigmentosum and trichothiodystrophy donors to the lethal action of UV-C. Mutat Res. 1992 Mar;273(2):127–135. [PubMed]
  • Cole J, Arlett CF, Norris PG, Stephens G, Waugh AP, Beare DM, Green MH. Elevated hprt mutant frequency in circulating T-lymphocytes of xeroderma pigmentosum patients. Mutat Res. 1992 Mar;273(2):171–178. [PubMed]
  • Lehmann AR, Kirk-Bell S, Arlett CF, Paterson MC, Lohman PH, de Weerd-Kastelein EA, Bootsma D. Xeroderma pigmentosum cells with normal levels of excision repair have a defect in DNA synthesis after UV-irradiation. Proc Natl Acad Sci U S A. 1975 Jan;72(1):219–223. [PubMed]
  • Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med. 1988 Jun 23;318(25):1633–1637. [PubMed]
  • Pichler E, Fritsch P. Xeroderma Pigmentosum: Tumorprophylaxe mit Etretinat. Hautarzt. 1984 Mar;35(3):159–161. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press